Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug to drug interactions and neuropsychological impact. What have we learned from real word evidence?

• Asıl Yazarlar: Nicola Pietrafusa (Yazar), Giovanni Falcicchio (Yazar), Emilio Russo (Yazar), Simona Lattanzi (Yazar), Bianca Goffredo (Yazar), Raffaele Simeoli (Yazar), Sara Cairoli (Yazar), Tiziana Corsetti (Yazar), Roberta Roberti (Yazar), Marina De Tommaso (Yazar), Federico Vigevano (Yazar), Angela La Neve (Yazar), Nicola Specchio (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2023-12-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: Cenobamate (CNB) is an anti-seizure medication (ASM) approved in 2021 in Europe for adjunctive treatment of focal-onset seizures in adults who were not adequately controlled with at least two previous ASMs.Methods: seizure outcome, treatment-emergent adverse events, neuropsychological pr...